PMID- 16353949
OWN - NLM
STAT- MEDLINE
DCOM- 20060118
LR  - 20181113
IS  - 1550-7416 (Electronic)
IS  - 1550-7416 (Linking)
VI  - 7
IP  - 3
DP  - 2005 Oct 27
TI  - Regulation of monoamine transporters: influence of psychostimulants and 
      therapeutic antidepressants.
PG  - E728-38
AB  - Synaptic neurotransmission in the central nervous system (CNS) requires the 
      precise control of the duration and the magnitude of neurotransmitter action at 
      specific molecular targets. At the molecular level, neurotransmitter signaling is 
      dynamically regulated by a diverse set of macromolecules including biosynthetic 
      enzymes, secretory proteins, ion channels, pre- and postsynaptic receptors and 
      transporters. Monoamines, 5-hydroxytryptamine or serotonin (5-HT), norepinephrine 
      (NE), and dopamine (DA) play an important modulatory role in the CNS and are 
      involved in numerous physiological functions and pathological conditions. 
      Presynaptic plasma membrane transporters for 5-HT (SERT), NE (NET), and DA (DAT), 
      respectively, control synaptic actions of these monoamines by rapidly clearing 
      the released amine. Monoamine transporters are the sites of action for widely 
      used antidepressants and are high affinity molecular targets for drugs of abuse 
      including cocaine, amphetamine, and 3,4-methylenedioxymetamphetamine (MDMA) 
      "Ecstasy." Monoamine transporters also serve as molecular gateways for 
      neurotoxins. Emerging evidence indicates that regulation of transporter function 
      and surface expression can be rapidly modulated by "intrinsic" transporter 
      activity itself, and antidepressant and psychostimulant drugs that block 
      monoamine transport have a profound effect on transporter regulation. Therefore, 
      disregulations in the functioning of monoamine transporters may underlie many 
      disorders of transmitter imbalance such as depression, attention deficit 
      hyperactivity disorder, and schizophrenia. This review integrates recent progress 
      in understanding the molecular mechanisms of monoamine transporter regulation, in 
      particular, posttranscriptional regulation by phosphorylation and trafficking 
      linked to cellular protein kinases, protein phosphatases, and transporter 
      interacting proteins. The review also discusses the possible role of 
      psychostimulants and antidepressants in influencing monoamine transport 
      regulation.
FAU - Jayanthi, Lankupalle D
AU  - Jayanthi LD
AD  - Department of Neurosciences, Medical University of South Carolina, Charleston, SC 
      29425, USA. jayanthi@musc.edu
FAU - Ramamoorthy, Sammanda
AU  - Ramamoorthy S
LA  - eng
GR  - DA016753/DA/NIDA NIH HHS/United States
GR  - MH062612/MH/NIMH NIH HHS/United States
GR  - P50DA015369/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20051027
PL  - United States
TA  - AAPS J
JT  - The AAPS journal
JID - 101223209
RN  - 0 (Antidepressive Agents)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Vesicular Monoamine Transport Proteins)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*metabolism
MH  - Central Nervous System Stimulants/*metabolism
MH  - Humans
MH  - Protein Binding/physiology
MH  - Vesicular Monoamine Transport Proteins/genetics/*physiology
PMC - PMC2751275
EDAT- 2005/12/16 09:00
MHDA- 2006/01/19 09:00
PMCR- 2006/10/27
CRDT- 2005/12/16 09:00
PHST- 2005/12/16 09:00 [pubmed]
PHST- 2006/01/19 09:00 [medline]
PHST- 2005/12/16 09:00 [entrez]
PHST- 2006/10/27 00:00 [pmc-release]
AID - 73728 [pii]
AID - 10.1208/aapsj070373 [doi]
PST - epublish
SO  - AAPS J. 2005 Oct 27;7(3):E728-38. doi: 10.1208/aapsj070373.